RSS-Feed abonnieren
DOI: 10.1055/s-0030-1250229
© Georg Thieme Verlag KG Stuttgart · New York
A Literature Review-Based Clinical Guide on the Use of Erythropoiesis-Stimulating Agents (ESA) in the Treatment of Patients with Gynaecological Malignancies and Related Anaemia
Klinischer literaturbasierter Leitfaden für die Anwendung von Erythropoese-stimulierenden Substanzen (ESA) in der Behandlung von Patientinnen mit gynäkologischen Malignomen und assoziierter AnämiePublikationsverlauf
received 6.2.2010
revised 31.5.2010
accepted 10.6.2010
Publikationsdatum:
18. August 2010 (online)
![](https://www.thieme-connect.de/media/gebfra/201008/lookinside/thumbnails/10.1055-s-0030-1250229-1.jpg)
Zusammenfassung
Fragestellung: Erythropoesestimulierende Substanzen (ESA) werden häufig bei Patienten mit chemotherapieinduzierter Anämie eingesetzt. Sie können den Hämoglobin-(Hb-)Wert korrigieren, den Bedarf von Bluttransfusionen reduzieren, sowie Fatigue und die Lebensqualität verbessern. Besonders relevant ist die Reduktion von Bluttransfusionen durch ESA, da Transfusionen mit erhöhter Mortalität vergesellschaftet sind. Obwohl von zahlreichen Vorteilen durch die Anwendung von ESA berichtet wurde, wird deren Anwendung dennoch kontrovers diskutiert. Neun klinische Studien mit Karzinomen der Brust, Zervix, des Hals- und Kopfbereichs, dem nicht kleinzelligen Bronchialkarzinom, und nicht myeloischen Malignomen haben einen negativen Einfluss von ESA auf das Überleben berichtet. Analysen dieser Studien haben jedoch ergeben, dass die Anwendung der ESA nicht entsprechend den Empfehlungen in Leitlinien und den zugelassenen Indikationen erfolgt ist (höhere ESA-Dosen als empfohlen; ESA-Behandlung nicht anämischer Patienten; Ziel-Hb oberhalb dem empfohlenen Wert von 12 g/dl; Radiotherapie ohne gleichzeitige Chemotherapie; keine tumorspezifische Therapie). Die breite Verwendung von ESA im nicht zugelassenen Bereich dürfte die wahrscheinlichste Ursache für den beobachteten negativen Effekt in den 9 oben erwähnten Studien sein. Zwei große Metaanalysen wurden in den letzten Jahren publiziert (Bennet 2008 [22] und Bohlius 2009 [23]). Von Bedeutung sind insbesondere Subgruppenanalysen, die eindeutig gezeigt haben, dass bei Patientinnen, die zusätzlich zur Gabe von ESA eine Chemotherapie erhalten hatten, keine erhöhte Mortalität in der ESA-Gruppe nachgewiesen werden konnte (HR 1,09 und HR 1,10; nicht signifikanter Unterschied). Schlussfolgerung: ESA sollten nur bei symptomatischen Patientinnen mit einem Hb-Wert < 10 g/dl während Chemotherapie angewendet werden. Der Zielbereich für Hämoglobin sollte nicht über 12 g/dl hinausgehen. In diesen Fällen ist keine erhöhte Mortalität zu erwarten. Dennoch muss bei Behandlung mit ESAs ein signifikant erhöhtes Risiko für die Entwicklung von venösen Thromboembolien einkalkuliert werden.
Schlüsselwörter
erythropoesestimulierende Substanzen - Erythropoetin - tumorassoziierte Anämie - Chemotherapie - Brustkrebs
References
- 1 Erypo® (epoetin alfa) summary of product characteristics. Vienna, Austria: Janssen-Cilag GmbH (Stand der Fachinfo 1/2010).
- 2 Neorecormon® (epoetin beta) summary of product characteristics. Vienna, Austria: Roche GmbH (Stand der Fachinfo).
- 3 Aranesp® (darbepoetin alfa) summary of product characteristics. Vienna, Austria: Amgen GmbH (Stand der Fachinfo 28.10.2009).
- 4 Gascon P. Evaluating erythropoietic agents for the treatment of anaemia in the oncology setting. Eur J Cancer. 2005; 41 2601-2612
- 5 Amato A C, Pescatori M. Effect of perioperative blood transfusions on recurrence of colorectal cancer: meta-analysis stratified on risk factors. Dis Colon Rectum. 1998; 41 570-585
- 6 Ludwig L, Crawford J, Oesterborg A et al. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol. 2009; 10 2838-2847
- 7 Leyland-Jones B, Semiglazov V, Pawlicki M et al. Maintaining normal haemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol. 2005; 23 5960-5972
- 8 Untch M, Fasching P A, Bauerfeind I et al. PREPARE trial. A randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF with a standard dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer: A preplanned interim analysis of efficacy at surgery. J Clin Oncol. 2008; 26 (suppl.) 517 abstr.
- 9 Thomas G, Ali S, Hoebers F J P et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 G/DL with erythropoietin vs. above 10.0 G/DL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer: A gynecologic oncology group study. Gynecol Oncol. 2008; 108 317-325
- 10 Temkin S M, Hellmann M, Serur E et al. Erythropoietin administration during primary treatment for locally advanced cervical carcinoma is associated with poor response to radiation. Int J Gynecol Cancer. 2006; 16 1855-1861
- 11 Henke M, Laszig R, Rübe C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003; 362 1255-1260
- 12 Overgaard J, Hoff C, Sand Hansen H the Danish Head and Neck Cancer Group (DAHANCA 10) et al. Randomized study of the importance of novel erythropoiesis stimulating protein (Aranesp®) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC). Eur J Cancer Suppl. 2007; 5 7 abstr.
- 13 Wright J R, Ung Y C, Julian J A et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol. 2007; 25 1027-1032
- 14 Smith jr. R E, Aapro M S, Ludwig H et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol. 2008; 26 1040-1050
- 15 Oncology drugs advisory committee briefing document. March 13, 2008. Available at. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4345b2-01-FDA.pdf accessed December 3, 2009
- 16 Oncology drugs advisory committee briefing information. May 10, 2007. Available at. http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4301b2-01-01-AMGEN.pdf accessed December 3, 2009
- 17 Aapro M S, Link H. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist. 2008; 13 (suppl. 3) 33-36
- 18 Ludwig H, Auberger T, Burghuber O. The use of erythropoiesis-stimulating proteins in anemic patients with malignant diseases. Wien Klin Wochenschr. 2008; 120 507-513
- 19 NCCN clinical practice guidelines in oncology. Cancer- and treatment-related anemia (V.2.2010). http://www.nccn.org/professionals/physician_gls/PDF/anemia.pdf accessed December 3, 2009
- 20 Glaspy J. ESAs to treat anemia-balancing the risks and benefits. Nat Rev Clin Oncol. 2009; 6 500-502
- 21 Bohlius J, Wilson J, Seidenfeld J et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006; 98 708-714
- 22 Bennett C L, Silver S M, Djulbegovic B et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated aneamia. JAMA. 2008; 299 914-924
- 23 Bohlius J, Schmidlin K, Brillant C et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet. 2009; 373 1532-1542
- 24 Del Mastro L, Venturini M, Lionetto R et al. Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol. 1997; 15 2715-2721
- 25 Demetri G D, Gabrilove J L, Blasi M V et al. Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy. Clin Breast Cancer. 2002; 3 45-51
- 26 Olsson A M, Svensson J H, Sundström J et al. Erythropoietin treatment in metastatic breast cancer – effects on Hb, quality of life and need for transfusion. Acta Oncol. 2002; 41 517-524
- 27 Chang J, Couture F, Young S et al. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol. 2005; 23 2597-2605
- 28 O'Shaughnessy J A, Vukelja S J, Holmes F A et al. Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. Clin Breast Cancer. 2005; 5 439-446
- 29 Möbus V, Lueck H, Thomssen C et al. The impact of epoetin-alpha on anemia, red blood cell (RBC) transfusions, and survival in breast cancer patients (pts) treated with dose-dense sequential chemotherapy: mature results of an AGO phase III study (ETC trial). J Clin Oncol. 2007; 25 (suppl. 18) 569 abstr.
- 30 Aapro M, Leonard R C, Barnadas A et al. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study. J Clin Oncol. 2008; 26 592-598
- 31 Nitz U, Oberhoff C, Reimer T et al. Adjuvant chemotherapy with or without darbepoetin in node-positive breast cancer: a safety analysis from the phase lll ARA Plus trial [abstract 4100]. Presented at the CTCR-AACR San Antonio Breast Cancer Symposium, San Antonio, Texas, December 10 – 14, 2008.
- 32 Blohmer J-U, Wurschmidt F, Petry U et al. Results with sequential adjuvant chemoradiotherapy with vs. without epoetin alfa for patients with high-risk cervical cancer: Results of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study. Ann Oncol. 2004; 15 (suppl. 3) iii128 abstr.
- 33 Wun T, Law L, Harvey D et al. Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer. 2003; 98 1514-1520
- 34 Lavey R S, Liu P Y, Greer B E et al. Recombinant human erythropoietin as an adjunct to radiation therapy and cisplatin for stage IIB-IVA carcinoma of the cervix: a Southwest Oncology Group study. Gynecol Oncol. 2004; 95 145-151
- 35 Bellati F, Pernice M, Manci N et al. Hemoglobin variation and blood transfusion rates in patients affected by locally advanced cervical cancer undergoing neo-adjuvant chemotherapy followed by radical surgery: the role of erythropoietic growth factors. Ann Oncol. 2007; 18 722-729
- 36 Strauss H G, Haensgen G, Dunst J et al. Effects of anemia correction with epoetin beta in patients receiving radiochemotherapy for advanced cervical cancer. Int J Gynecol Cancer. 2008; 18 515-524
- 37 Gupta S, Singh P K, Bisth S S et al. Role of recombinant human erythropoietin in patients of advanced cervical cancer treated “by chemoradiotherapy”. Cancer Biol Ther. 2009; 8 13-17
- 38 Welch R S, James R D, Wilkinson P M et al. Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer. Cancer J Sci Am. 1995; 1 261-266
- 39 ten Bokkel Huinink W W, de Swart C A, van Toorn D W et al. Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med Oncol. 1998; 15 174-182
- 40 Marinaccio M, Mele E, Giotta F et al. Pretreatment normalization of mild anemia with epoetin alfa: Impact on the outcome in epithelial ovarian cancer patients. Proc Am Soc Clin Oncol. 2003; 22 1952 abstr.
- 41 Reed N, Chan S, Hayward C et al. Impact of epoetin beta on the survival of anemic patients with ovarian cancer receiving platinum-based chemotherapy. J Clin Oncol. 2005; 23 (16S) 5102 abstr.
- 42 Wilkinson P M, Antonopoulos M, Lahousen M EPO-INT-45 Study Group et al. Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial. Br J Cancer. 2006; 94 947-954
- 43 Volgger B, Petru E, Angleitner-Boubenizek L et al. Erythropoetin beta twice weekly versus standard therapy in patients with gynaecological malignancies – a randomised Austrian AGO trial. Anticancer Res. 2008; 28 3977-3984
- 44 Leyland Jones B. BEST Investigators and Study Group . Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol. 2003; 4 459-460
- 45 Kamat A A, Coleman R L. Erythropoeisis-stimulating agents (ESAs) in cervix cancer. The “black box” paradox. Cancer Biol Ther. 2009; 8 18-20
- 46 Pirker R, Ramlau R A, Schuette W et al. Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. J Clin Oncol. 2008; 26 2342-2349
- 47 Grote T, Yeilding A L, Castillo R et al. Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2005; 23 9377-9386
- 48 Crawford J, Robert F, Perry M C et al. A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy. J Thorac Oncol. 2007; 2 210-220
- 49 Vansteenkiste J, Pirker R, Massuti B Aranesp 980297 Study Group et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst. 2002; 94 1211-1220
- 50 Hedenus M, Vansteenkiste J, Kotasek D et al. Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials. J Clin Oncol. 2005; 23 6941-6948
- 51 Littlewood T J, Bajetta E, Nortier J W Epoetin Alfa Study Group et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001; 19 2865-2874
- 52 Ludwig H, Fritz E, Leitgeb C et al. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood. 1994; 84 1056-1063
- 53 Repetto L, Moeremans K, Annemans L. European Organisation for Research and Treatment of Cancer . European guidelines for the management of chemotherapy-induced anaemia and health economic aspects of treatment. Cancer Treat Rev. 2006; 32 (suppl. 2) S5-S9
- 54 Groopman J E, Itri L M. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999; 91 1616-1634
- 55 Dranitsaris G, Clemons M, Verma S et al. Chemotherapy-induced anaemia during adjuvant treatment for breast cancer: development of a prediction model. Lancet Oncol. 2005; 6 856-863
- 56 Pirker R, Ramlau R, Schuette W et al. A phase 3 randomized, double blind, placebo-controlled study of patients with previously untreated extensive-stage small cell lung cancer (SCLC) treated with platinum plus etoposide chemotherapy with or without darbepoetin alfa. J Thorac Surgery. 2007; 2 (suppl. 4) S433-S434
- 57 Volgger B, Petru E, Angleitner-Boubenizek L et al. Higher rate of thrombosis in erythropoietin β twice weekly versus standard therapy in patients with gynecologic malignancy: An Austrian AGO trial. Int J Gynecol Cancer. 2005; 15 62 abstr.
- 58 Glaspy J, Österborg A, Ludwig H et al. Evaluation of the association between hemoglobin (Hb) events and safety outcomes in cancer patients (pts) with chemotherapy-induced anemia (CIA): an integrated analysis of patient-level data from 6 randomized, placebo-controlled trials (RCTs) of darbepoetin alpha (DA). Eur J Cancer. 2007; 5 (suppl. 4) P1120 abstr.
- 59 Rizzo J D, Somerfield M R, Hagerty K L et al. American Society of Hematology/American Society of Clinical Oncology 2007 clinical practice guideline update of epoetin and darbepoetin. Blood. 2007; 111 25-41
- 60 Larsson A M, Jirström K, Fredlund E et al. Erythropoietin receptor expression and correlation to tamoxifen response and prognosis in breast cancer. Clin Cancer Res. 2009; 15 5552-5559
- 61 Ross S D, Allen I E, Henry D H et al. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Clin Ther. 2006; 28 801-831
- 62 Aapro M S, Vaupel P. Erythropoietin: effects on life expectancy in patients with cancer-related anaemia. Curr Med Res Opin. 2006; 22 (suppl. 4) S5-S13
- 63 Auerbach M, Ballard H, Trout J R et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol. 2004; 22 1301-1307
- 64 Henry D H, Dahl N V, Auerbach M et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist. 2007; 12 231-242
- 65 Candelaria M, Cetina L, Dueñas-González A. Anemia in cervical cancer patients: implications for iron supplementation therapy. Med Oncol. 2005; 22 161-168
- 66 Meden H, Conrad A, Rath W. [New oncological therapy approaches with haematopoietic growth factors]. Geburtsh Frauenheilk. 1993; 53 222-229
- 67 Gerber B, Arndt M, Wesselburg C et al. [Responsibility for patient education and incidence of homologous blood transfusions in unilateral breast cancer operations]. Geburtsh Frauenheilk. 1995; 55 572-576
- 68 Petru E, Angleitner-Boubenizek L, Reinthaller A et al. Wöchentlich Docetaxel und Irinotecan beim Platin-refraktären und -resistenten Ovarialkarzinom – Eine multizentrische Phase II Studie der österreichischen AGO. Geburtsh Frauenheilk. 2007; 68 504-505
For the AGO/OEGGG: Univ. Prof. Dr. Edgar Petru
Univ. Klinik für Frauenheilkunde und Geburtshilfe
Auenbruggerplatz 14
8036 Graz
Österreich
eMail: edgar.petru@medunigraz.at